摘要
目的探讨拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床疗效。方法 68例失代偿期乙型肝炎肝硬化患者在综合护肝及对症治疗基础上,治疗组22例,给予拉米夫定100mg/d联合阿德福韦酯10mg/d口服;对照A组23例,给予阿德福韦酯10mg/d口服;对照B组23例,给予拉米夫定100mg/d口服,治疗6个月。治疗前后都观察肝功能、血清乙型肝炎病毒脱氧核糖核酸(HBVDNA)水平以及变化。结果拉米夫定和阿德福韦酯联合治疗组与对照A组和对照B组HBVDNA阴转率分别为81.8%、47.8%和43.5%,联合治疗组明显优于对照组A组及B组(P<0.05);肝功能Child-Pugh评分分别为(6.8±1.4)分、(7.2±1.5)分和(7.4±1.9)分,联合治疗组明显优于两个对照组(P<0.05)。结论拉米夫定联合阿德福韦酯抗病毒治疗失代偿期乙型肝炎肝硬化优于单独使用拉米夫定或阿德福韦酯治疗,且不易产生耐药性,并可起互补作用,患者能长期稳定病情。
Objective To investigate the clinical efficacy of lamivudine and adefovir dipivoxil therapy in patients with decompensated liver cirrhosis resulting from hepatitis B.Methods 68 patients with decompensated liver cirrhosis resulting from hepatitis B were included and 22 patients with lamivudine 100 mg and adefovir 10 mg once daily,23 with lamivudine 100 mg once daily and 23 with adefovir dipivoxil 10 mg once daily for more than six months.Results The negative-transformed rate of HBV DNA in combined group,lamivudine group and adefovir dipivoxil group were 81.8%,47.8% and 43.5%,respectively;and the Child-Pugh scores were （6.8±1.4） scores,（7.2±1.5） scores and （7.4±1.9） scores,respectively.Conclusion Combination of lamivudine and adefovir dipivoxil in treatment of decompensated liver cirrhosis resulting from hepatitis B has an advantage over lamivudine or adefovir dipivoxil treatment alone.Lamivudine combined with adefovir dipivoxil treatment of hepatitis B cirrhosis shows no resistance and patients could receive a long-term drugs with stable condition.
出处
《临床荟萃》
CAS
2010年第15期1314-1316,共3页
Clinical Focus
关键词
肝硬化
拉米夫定
肝炎
乙型
cirrhosis
lamivudine
hepatitis
B type
